Market open
Incyte/$INCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Incyte
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Ticker
$INCY
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,617
Website
Incyte Metrics
BasicAdvanced
$11B
393.13
$0.15
0.76
-
Price and volume
Market cap
$11B
Beta
0.76
52-week high
$82.15
52-week low
$50.35
Average daily volume
2.3M
Financial strength
Current ratio
2.039
Quick ratio
1.705
Long term debt to equity
1.101
Total debt to equity
1.101
Interest coverage (TTM)
52.28%
Management effectiveness
Return on assets (TTM)
0.86%
Return on equity (TTM)
0.76%
Valuation
Price to earnings (TTM)
393.133
Price to revenue (TTM)
2.88
Price to book
3.31
Price to tangible book (TTM)
3.59
Price to free cash flow (TTM)
51.933
Growth
Revenue change (TTM)
14.76%
Earnings per share change (TTM)
-94.34%
3-year revenue growth (CAGR)
12.41%
3-year earnings per share growth (CAGR)
-67.25%
What the Analysts think about Incyte
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Incyte stock.
Incyte Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Incyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Incyte News
AllArticlesVideos
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
Business Wire·3 hours ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Incyte stock?
Incyte (INCY) has a market cap of $11B as of April 25, 2025.
What is the P/E ratio for Incyte stock?
The price to earnings (P/E) ratio for Incyte (INCY) stock is 393.13 as of April 25, 2025.
Does Incyte stock pay dividends?
No, Incyte (INCY) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Incyte dividend payment date?
Incyte (INCY) stock does not pay dividends to its shareholders.
What is the beta indicator for Incyte?
Incyte (INCY) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.